GlassScriptPhysician profile
Sanjay S Srivatsa
NPI 1588603369
$36,756.19
in general payments reported to CMS, 2019-2025
39 companies · $5,770 in 2025
The $5,770 reported for 2025 was more than what 92% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,544 · 2020: $5,781 · 2021: $4,985 · 2022: $4,808 · 2023: $5,151 · 2024: $4,718 · 2025: $5,770.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $11K · Food and Beverage: $4,343 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $11,200.00 |
| Food and Beverage | $4,343.18 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $27,791.67 | 2019-2025 | Venacure 1470 Pro |
| Amgen INC. | $3,340.29 | 2019-2025 | Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $762.05 | 2021-2025 | |
| Amarin Pharma, INC. | $612.47 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $447.71 | 2021-2025 | Verquvo |
| Actelion Pharmaceuticals US, INC. | $396.62 | 2019-2024 | Opsumit, Uptravi |
| Medtronic, INC. | $386.39 | 2021-2023 | In.Pact Admiral, Reveal Linq |
| Astrazeneca Pharmaceuticals LP | $298.75 | 2019-2024 | Farxiga, Lokelma |
| Pfizer INC. | $269.31 | 2019-2025 | |
| Akcea Therapeutics, INC. | $259.52 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $237.86 | 2021-2022 | |
| Boston Scientific Corporation | $215.59 | 2021-2025 | Varithena Administration Pack |
| Smith+Nephew, INC. | $205.22 | 2019-2025 | Collagenase Santyl, Grafix Pl |
| Medtronic Vascular, INC. | $197.58 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $153.45 | 2021-2024 | Onpattro |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $143.99 | 2019-2025 | Mounjaro, Trulicity |
| Novartis Pharmaceuticals Corporation | $115.13 | 2021-2025 | |
| Scpharmaceuticals INC. | $113.47 | 2023-2025 | |
| Biocompatibles, INC. | $101.05 | 2019 | |
| Baxter Healthcare | $98.92 | 2024-2025 | Hillrom - Carnation Ambulatory Monitor, Hillrom - Cardiac Ambulatory Monitor |
| Philips North America LLC | $73.67 | 2020-2025 | (5044) Mcot, Ambulatory Monitoring & Diagnostics Undivided |
| Lexicon Pharmaceuticals, INC. | $66.62 | 2023-2024 | Inpefa |
| Bardy Diagnostics, INC. | $50.49 | 2021-2022 | |
| Abiomed | $49.35 | 2023-2025 | Impella |
| Organogenesis INC. | $39.39 | 2020-2021 | |
| Cordis US Corp. | $37.96 | 2024 | Radial 360 |
| Novo Nordisk INC | $34.88 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $34.07 | 2020-2021 | |
| Abbott Laboratories | $28.76 | 2023 | Freestyle Libre 2 |
| Tactile Systems Technology INC | $26.86 | 2021 | |
| Averitas Pharma INC. | $23.71 | 2024 | Qutenza |
| Nevro Corp. | $23.67 | 2023 | Senza |
| Resmed Corp | $20.81 | 2022 | |
| Biogen, INC. | $20.33 | 2023 | |
| Braemar Manufacturing, LLC | $17.37 | 2019 | |
| Esperion Therapeutics, INC. | $16.31 | 2020 | |
| Glaxosmithkline, LLC. | $15.85 | 2025 | Shingrix |
| Inspire Medical Systems, INC. | $14.53 | 2024 | Inspire |
| Horizon Therapeutics Plc | $14.52 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjay Srivatsa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.